'%3e%3cg id='Final-Copy-2_2_' transform='translate(1275.000000, 200.000000)'%3e%3cpath class='st0' d='M7.4,12.8h6.8l3.1-11.6H7.4C4.2,1.2,1.6,3.8,1.6,7S4.2,12.8,7.4,12.8z'/%3e%3c/g%3e%3c/g%3e%3c/g%3e%3cg id='final---dec.11-2020'%3e%3cg id='_x30_208-our-toggle' transform='translate(-1275.000000, -200.000000)'%3e%3cg id='Final-Copy-2' transform='translate(1275.000000, 200.000000)'%3e%3cpath class='st1' d='M22.6,0H7.4c-3.9,0-7,3.1-7,7s3.1,7,7,7h15.2c3.9,0,7-3.1,7-7S26.4,0,22.6,0z M1.6,7c0-3.2,2.6-5.8,5.8-5.8 h9.9l-3.1,11.6H7.4C4.2,12.8,1.6,10.2,1.6,7z'/%3e%3cpath id='x' class='st2' d='M24.6,4c0.2,0.2,0.2,0.6,0,0.8l0,0L22.5,7l2.2,2.2c0.2,0.2,0.2,0.6,0,0.8c-0.2,0.2-0.6,0.2-0.8,0 l0,0l-2.2-2.2L19.5,10c-0.2,0.2-0.6,0.2-0.8,0c-0.2-0.2-0.2-0.6,0-0.8l0,0L20.8,7l-2.2-2.2c-0.2-0.2-0.2-0.6,0-0.8 c0.2-0.2,0.6-0.2,0.8,0l0,0l2.2,2.2L23.8,4C24,3.8,24.4,3.8,24.6,4z'/%3e%3cpath id='y' class='st3' d='M12.7,4.1c0.2,0.2,0.3,0.6,0.1,0.8l0,0L8.6,9.8C8.5,9.9,8.4,10,8.3,10c-0.2,0.1-0.5,0.1-0.7-0.1l0,0 L5.4,7.7c-0.2-0.2-0.2-0.6,0-0.8c0.2-0.2,0.6-0.2,0.8,0l0,0L8,8.6l3.8-4.5C12,3.9,12.4,3.9,12.7,4.1z'/%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
Your Privacy Choices
AATB Advocacy Helps Secure Delay in CMS LCD Implementation for Skin Substitute Grafts
On Friday, April 11, the Centers for Medicare & Medicaid Services (CMS) announced that the final Local Coverage Determinations (LCDs) for Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers will now take effect on January 1, 2026.
AATB Urges FDA Commissioner to Rescind Sepsis and Mtb Guidance Documents
As part of our continued advocacy efforts, AATB—alongside AOPO and EBAA—sent a joint letter today to newly confirmed FDA Commissioner Dr. Marty Makary urging the immediate rescission of two guidance documents issued as final on January 6, 2025.
AATB Applauds Reintroduction of the Shandra Eisenga Human Cell and Tissue Product Safety Act
AATB commends Representatives John Moolenaar (R-MI) and Debbie Dingell (D-MI) for reintroducing the Shandra Eisenga Human Cell and Tissue Product Safety Act, a vital piece of legislation aimed at preventing tuberculosis (TB) infections linked to tissue transplants.
Join Us in Atlanta for the 2025 AATB Annual Meeting – Submit Your Session Proposals and Abstracts!
Mark your calendars for the 2025 AATB Annual Meeting, which will take place October 12-15, 2025, in Atlanta, GA. This must-attend event will bring together professionals from across the tissue donation and transplantation community to connect, innovate, and advance meaningful progress.
AATB Advocates for Tissue Banking Policy on Capitol Hill
Earlier this week, AATB representatives and members had the incredible opportunity to visit Capitol Hill, to advocate for key issues impacting the tissue banking community.
AATB Eliminates Additional Fees for Satellite Site Inspections
AATB is pleased to announce that we will no longer charge institutional members a supplemental fee for satellite site inspections conducted as part of the routine three-year accreditation cycle.
FDA Revises Implementation Date for Sepsis and Mtb Guidance
The FDA has announced a revised implementation date of May 4, 2025, for its recently issued guidance documents.
Medicare Coverage Updates on Skin Substitutes
On Friday, January 24, 2025, all seven Medicare Administrative Contractors (MACs) announced a delay in implementing final skin substitute Local Coverage Determinations (LCDs). Initially set to take effect on February 12, 2025, the implementation date has been postponed to April 13, 2025.
Navigating Regulatory Changes: AATB's Response to the FDA Guidance Documents and Executive Order
In light of recent regulatory developments, it is essential for stakeholders in the tissue banking community to stay informed about potential changes to FDA guidance documents.